The Bill and Melinda Gates Foundation has invested millions of dollars in a French biotech company working to rebuild the immune systems of cancer patients, as the global elite continue making major moves in the turbo cancer economy.

In December, Pfizer made a $43 billion dollar bet that turbo cancers are going to become the most profitable area of medical treatment, shocking the medical world by acquiring Seagen, a small drug company that treats cancers and currently makes just $2 billion per year.